Journal article · 2026
Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
New England Journal of Medicine, 395(19), 1921–1931 · Published 23 October 2026 · DOI 10.1056/nejmoa2607544
In brief
“Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial” is a 2026 journal article by Jonathan Barratt and 23 co-authors, published in New England Journal of Medicine. OpenAlex counts 2 citations as of 16 November 2026, which puts it in the top 5% of works published in 2026 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 2
- Most cited in
- 2026 (2)
- Field-weighted impact
- 7.81
- References
- 24
- Authors
- 24
Abstract
BACKGROUND: In patients with IgA nephropathy, complement activation drives glomerular inflammation, which leads to hematuria, proteinuria, and nephron loss. Ravulizumab is a terminal complement inhibitor that prevents formation of C5a and C5b-9. METHODS: of body-surface area and proteinuria (24-hour urinary protein-to-creatinine ratio [with protein and creatinine both measured in grams] of ≥0.75 or total urinary… Read the full abstract at the publisher.
Excerpt. This paper is not open access.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Barratt, J., Farag, Y. M., Rice, K. C., Cammett, T. J., Inker, L. A., Trimarchi, H., Bruchfeld, A. N., Heerspink, H. J., Liew, A., Carroll, K., Zhang, H., Norouzi, S., Hou, S., Park, S., Valdivia, M. Á. P., Radhakrishnan, J., Suzuki, Y., Schneider, B., Marsala, J., . . . Lafayette, R. A. (2026). Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial. New England Journal of Medicine, 395(19), 1921–1931. https://doi.org/10.1056/nejmoa2607544
MLA 9
Barratt, Jonathan, et al. “Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial.” New England Journal of Medicine, vol. 395, no. 19, 2026, pp. 1921–1931. https://doi.org/10.1056/nejmoa2607544.
Chicago
Barratt, Jonathan, Youssef M.K. Farag, Kara Creamer Rice, Tobin J. Cammett, Lesley A. Inker, Hernán Trimarchi, Annette N. Bruchfeld, et al. 2026. “Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial.” New England Journal of Medicine 395 (19): 1921–1931. https://doi.org/10.1056/nejmoa2607544.
Harvard
Barratt, J. et al. (2026) ‘Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial’, New England Journal of Medicine, 395(19), pp. 1921–1931. doi:10.1056/nejmoa2607544.
IEEE
J. Barratt et al., “Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial,” New England Journal of Medicine, vol. 395, no. 19, pp. 1921–1931, 2026, doi: 10.1056/nejmoa2607544.
BibTeX
@article{barratt2026ravulizumab,
title = {{Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial}},
author = {Barratt, Jonathan and Farag, Youssef M.K. and Rice, Kara Creamer and Cammett, Tobin J. and Inker, Lesley A. and Trimarchi, Hernán and Bruchfeld, Annette N. and Heerspink, Hiddo J.L. and Liew, Adrian and Carroll, Kevin and Zhang, Hong and Norouzi, Sayna and Hou, Shuang and Park, Sehoon and Valdivia, Miguel Ángel Pérez and Radhakrishnan, Jai and Suzuki, Yusuke and Schneider, Bonnie and Marsala, John and Carrillo-Infante, Cynthia and Lake, Stephen L. and Singh, Ajay K. and NOLAN, STEPHEN T. and Lafayette, Richard A.},
journal = {New England Journal of Medicine},
year = {2026},
volume = {395},
number = {19},
pages = {1921--1931},
doi = {10.1056/nejmoa2607544},
url = {https://doi.org/10.1056/nejmoa2607544}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- ravulizumab
- IgA nephropathy
- complement inhibition
- C5a receptor
- proteinuria
- urine protein-to-creatinine ratio
- glomerular inflammation
- adverse events
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Barratt, J., Farag, Y. M., Rice, K. C., Cammett, T. J., Inker, L. A., Trimarchi, H., Bruchfeld, A. N., Heerspink, H. J., Liew, A., Carroll, K., Zhang, H., Norouzi, S., Hou, S., Park, S., Valdivia, M. Á. P., Radhakrishnan, J., Suzuki, Y., Schneider, B., Marsala, J., . . . Lafayette, R. A. (2026). Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial. New England Journal of Medicine, 395(19), 1921–1931. https://doi.org/10.1056/nejmoa2607544
How many times has this paper been cited?
2 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Jonathan Barratt, Youssef M.K. Farag, Kara Creamer Rice, Tobin J. Cammett, Lesley A. Inker, Hernán Trimarchi, Annette N. Bruchfeld, Hiddo J.L. Heerspink, Adrian Liew, Kevin Carroll, Hong Zhang, Sayna Norouzi and 12 more.
What is the DOI of this paper?
10.1056/nejmoa2607544, permanently at https://doi.org/10.1056/nejmoa2607544. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.